{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:32:02Z","timestamp":1782739922394,"version":"3.54.5"},"reference-count":79,"publisher":"National Institute for Health and Care Research","issue":"63","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["08\/71\/01"],"award-info":[{"award-number":["08\/71\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title><jats:p>Ureteric colic, the term used to describe the pain felt when a stone passes down the ureter from the kidney to the bladder, is a frequent reason for people to seek emergency health care. Treatment with the muscle-relaxant drugs tamsulosin hydrochloride (Petyme, TEVA UK Ltd) and nifedipine (Coracten<jats:sup>\u00ae<\/jats:sup>, UCB Pharma Ltd) as medical expulsive therapy (MET) is increasingly being used to improve the likelihood of spontaneous stone passage and lessen the need for interventional procedures. However, there remains considerable uncertainty around the effectiveness of these drugs for routine use.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title><jats:p>To determine whether or not treatment with either tamsulosin 400\u2009\u00b5g or nifedipine 30\u2009mg for up to 4 weeks increases the rate of spontaneous stone passage for people with ureteric colic compared with placebo, and whether or not it is cost-effective for the UK NHS.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-3\"><jats:title>Design<\/jats:title><jats:p>A pragmatic, randomised controlled trial comparing two active drugs, tamsulosin and nifedipine, against placebo. Participants, clinicians and trial staff were blinded to treatment allocation. A cost\u2013utility analysis was performed using data gathered during trial participation.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-4\"><jats:title>Setting<\/jats:title><jats:p>Urology departments in 24 UK NHS hospitals.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-5\"><jats:title>Participants<\/jats:title><jats:p>Adults aged between 18 and 65 years admitted as an emergency with a single ureteric stone measuring \u2264\u200910\u2009mm, localised by computerised tomography, who were able to take trial medications and complete trial procedures.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-6\"><jats:title>Interventions<\/jats:title><jats:p>Eligible participants were randomised 1\u2009:\u20091\u2009:\u20091 to take tamsulosin 400\u2009\u00b5g, nifedipine 30\u2009mg or placebo once daily for up to 4 weeks to make the following comparisons: tamsulosin or nifedipine (MET) versus placebo and tamsulosin versus nifedipine.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-7\"><jats:title>Main outcome measures<\/jats:title><jats:p>The primary effectiveness outcome was the proportion of participants who spontaneously passed their stone. This was defined as the lack of need for active intervention for ureteric stones at up to 4 weeks after randomisation. This was determined from 4- and 12-week case-report forms completed by research staff, and from the 4-week participant self-reported questionnaire. The primary economic outcome was the incremental cost per quality-adjusted life-year (QALY) gained over 12 weeks. We estimated costs from NHS sources and calculated QALYs from participant completion of the European Quality of Life-5 Dimensions health status questionnaire 3-level response (EQ-5D-3L\u2122) at baseline, 4 weeks and 12 weeks.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-8\"><jats:title>Results<\/jats:title><jats:p>Primary outcome analysis included 97% of the 1167 participants randomised (378\/391 tamsulosin, 379\/387 nifedipine and 379\/399 placebo participants). The proportion of participants who spontaneously passed their stone did not differ between MET and placebo [odds ratio (OR) 1.04, 95% confidence interval (CI) 0.77 to 1.43; absolute difference 0.8%, 95% CI \u20134.1% to 5.7%] or between tamsulosin and nifedipine [OR 1.06, 95% CI 0.74 to 1.53; absolute difference 1%, 95% CI \u20134.6% to 6.6%]. There was no evidence of a difference in QALYs gained or in cost between the trial groups, which means that the use of MET would be very unlikely to be considered cost-effective. These findings were unchanged by extensive sensitivity analyses around predictors of stone passage, including sex, stone size and stone location.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-9\"><jats:title>Conclusions<\/jats:title><jats:p>Tamsulosin and nifedipine did not increase the likelihood of stone passage over 4 weeks for people with ureteric colic, and use of these drugs is very unlikely to be cost-effective for the NHS. Further work is required to investigate the phenomenon of large, high-quality trials showing smaller effect size than meta-analysis of several small, lower-quality studies.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-10\"><jats:title>Trial registration<\/jats:title><jats:p>Current Controlled Trials ISRCTN69423238. European Clinical Trials Database (EudraCT) number 2010\u2013019469\u201326.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-11\"><jats:title>Funding<\/jats:title><jats:p>This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in<jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 19, No. 63. See the NIHR Journals Library website for further project information.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta19630","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T09:37:17Z","timestamp":1438767437000},"page":"1-172","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)"],"prefix":"10.3310","volume":"19","clinical-trial-number":[{"clinical-trial-number":"isrctn69423238","registry":"10.18810\/isrctn","type":"results"}],"author":[{"given":"Robert","family":"Pickard","sequence":"first","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Starr","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"MacLennan","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kilonzo","sequence":"additional","affiliation":[{"name":"Health Economics Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lam","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Thomas","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Burr","sequence":"additional","affiliation":[{"name":"School of Medicine, University of St Andrews, St Andrews, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Norrie","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"McPherson","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"McDonald","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Shearer","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Gillies","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Anson","sequence":"additional","affiliation":[{"name":"St George\u2019s Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Boachie","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"N\u2019Dow","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Burgess","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Clark","sequence":"additional","affiliation":[{"name":"Stone Patient Advisory Group, Section of Endourology, British Association of Urological Surgeons, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cameron","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"McClinton","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, University of Aberdeen, Aberdeen, UK"},{"name":"Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2015,8]]},"reference":[{"key":"key20150804130551682_ref1-bib1","volume-title":"Kidney Stones","author":"American Urological Association","year":"2012"},{"key":"key20150804130551682_ref1-bib2","doi-asserted-by":"publisher","first-page":"c91","DOI":"10.1159\/000102995","article-title":"Quality of life of patients with nephrolithiasis and recurrent painful renal colic","volume":"106","author":"Diniz","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"key20150804130551682_ref1-bib3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/bjs.1800590112","article-title":"The effects of calculi on ureteral function","volume":"59","author":"Ross","year":"1972","journal-title":"Br J Surg"},{"key":"key20150804130551682_ref1-bib4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrurol.2012.253","article-title":"Stones in 2012: epidemiology, prevention and redefining therapeutic standards","volume":"10","author":"Neisius","year":"2013","journal-title":"Nature Rev Urol"},{"key":"key20150804130551682_ref1-bib5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(01)05782-8","article-title":"Recurrent renal stone disease \u2013 advances in pathogenesis and clinical management","volume":"358","author":"Bihl","year":"2001","journal-title":"Lancet"},{"key":"key20150804130551682_ref1-bib6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1258\/0004563011900623","article-title":"Clinical investigation and management of patients with renal stones","volume":"38","author":"Wilkinson","year":"2001","journal-title":"Ann Clin Biochem"},{"key":"key20150804130551682_ref1-bib7","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/01.ju.0000152082.14384.d7","article-title":"Urologic diseases in America project: urolithiasis","volume":"173","author":"Pearle","year":"2005","journal-title":"J Urol"},{"key":"key20150804130551682_ref1-bib8","doi-asserted-by":"publisher","first-page":"e5499","DOI":"10.1136\/bmj.e5499","article-title":"Management of renal colic","volume":"345","author":"Bultitude","year":"2012","journal-title":"BMJ"},{"key":"key20150804130551682_ref1-bib9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1464-410X.2011.10495.x","article-title":"Trends in urological stone disease","volume":"109","author":"Turney","year":"2012","journal-title":"BJU Int"},{"key":"key20150804130551682_ref1-bib10","volume-title":"Hospital Episode Statistics, Admitted Patient Care, England \u2013 2012\u201313: Procedures and Interventions","author":"Health and Social Care Information Centre","year":"2013"},{"key":"key20150804130551682_ref1-bib11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/bmj.38119.581991.55","article-title":"Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic","volume":"328","author":"Holdgate","year":"2004","journal-title":"BMJ"},{"key":"key20150804130551682_ref1-bib12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.annemergmed.2006.03.013","article-title":"Intravenous morphine plus ketorolac is superior to either drug alone for treatment of acute renal colic","volume":"48","author":"Safdar","year":"2006","journal-title":"Ann Emerg Med"},{"key":"key20150804130551682_ref1-bib13","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.eururo.2007.09.039","article-title":"2007 Guideline for the management of ureteral calculi","volume":"52","author":"Preminger","year":"2007","journal-title":"Eur Urol"},{"key":"key20150804130551682_ref1-bib14","doi-asserted-by":"publisher","first-page":"CD008509","DOI":"10.1002\/14651858.cd008509.pub2","article-title":"Alpha-blockers as medical expulsive therapy for ureteral stones","volume":"4","author":"Campschroer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key20150804130551682_ref1-bib15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2009.06.012","article-title":"Medical therapy to facilitate the passage of stones: what is the evidence?","volume":"56","author":"Seitz","year":"2009","journal-title":"Eur Urol"},{"key":"key20150804130551682_ref1-bib16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.eururo.2012.01.009","article-title":"Contemporary management of ureteral stones","volume":"61","author":"Bader","year":"2012","journal-title":"Eur Urol"},{"key":"key20150804130551682_ref1-bib17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.juro.2012.10.031","article-title":"Clinical effectiveness protocols for imaging in the management of ureteral calculous disease: AUA technology assessment","volume":"189","author":"Fulgham","year":"2013","journal-title":"J Urol"},{"key":"key20150804130551682_ref1-bib18","volume-title":"Committee on Medical Aspects of Radiation in the Environment (COMARE) 16th Report: Patient Radiation Dose Issues Resulting from the Use of CT in the UK","author":"Public Health England","year":"2014"},{"key":"key20150804130551682_ref1-bib19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2214\/ajr.178.1.1780101","article-title":"Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT","volume":"178","author":"Coll","year":"2002","journal-title":"Am J Roentgenol"},{"key":"key20150804130551682_ref1-bib20","doi-asserted-by":"publisher","first-page":"CD004926","DOI":"10.1002\/14651858.cd004926.pub3","article-title":"Fluids and diuretics for acute ureteric colic","volume":"2","author":"Worster","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20150804130551682_ref1-bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000475031","article-title":"Oral diclofenac in the prophylactic treatment of recurrent renal colic. A double-blind comparison with placebo","volume":"28","author":"Laerum","year":"1995","journal-title":"Eur Urol"},{"key":"key20150804130551682_ref1-bib22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1089\/end.2008.0615","article-title":"Emergency room management of ureteral calculi: current practices","volume":"23","author":"Phillips","year":"2009","journal-title":"J Endourol"},{"key":"key20150804130551682_ref1-bib23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/01.ju.0000165337.37317.4c","article-title":"Is there a role for antimuscarinics in renal colic? A randomized controlled trial","volume":"174","author":"Holdgate","year":"2005","journal-title":"J Urol"},{"key":"key20150804130551682_ref1-bib24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(06)69474-9","article-title":"Medical therapy to facilitate urinary stone passage: a meta-analysis","volume":"368","author":"Hollingsworth","year":"2006","journal-title":"Lancet"},{"key":"key20150804130551682_ref1-bib25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1464-410X.2006.06346.x","article-title":"A comparative in vitro study to determine the beneficial effect of calcium-channel and alpha(1)-adrenoceptor antagonism on human ureteric activity","volume":"98","author":"Davenport","year":"2006","journal-title":"BJU Int"},{"key":"key20150804130551682_ref1-bib26","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1021\/jm00018a001","article-title":"Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification","volume":"38","author":"Hieble","year":"1995","journal-title":"J Med Chem"},{"key":"key20150804130551682_ref1-bib27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3109\/13813459309003918","article-title":"The effect of nifedipine and verapamil on rhythmic contractions of human isolated ureter","volume":"101","author":"Sahin","year":"1993","journal-title":"Arch Int Physiol Biochim Biophys"},{"key":"key20150804130551682_ref1-bib28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-3-642-16499-6_14","article-title":"\u03b1(1)-Adrenoceptors in the urinary tract","volume":"202","author":"Yamada","year":"2011","journal-title":"Handbook Exp Pharmacol"},{"key":"key20150804130551682_ref1-bib29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2125.1982.tb01439.x","article-title":"A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects","volume":"13","author":"Elliott","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"key20150804130551682_ref1-bib30","first-page":"21","article-title":"Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia","volume":"32","author":"Lepor","year":"1988","journal-title":"Urology"},{"key":"key20150804130551682_ref1-bib31","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1476-5381.1993.tb13762.x","article-title":"Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract","volume":"109","author":"Lefevre-Borg","year":"1993","journal-title":"Br J Pharmacol"},{"key":"key20150804130551682_ref1-bib32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.bjp.0700907","article-title":"The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes","volume":"120","author":"Noble","year":"1997","journal-title":"Br J Pharmacol"},{"key":"key20150804130551682_ref1-bib33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/(SICI)1097-0045(19970915)33:1<55::AID-PROS9>3.0.CO;2-8","article-title":"Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes","volume":"33","author":"Richardson","year":"1997","journal-title":"Prostate"},{"key":"key20150804130551682_ref1-bib34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1600-0773.1978.tb02244.x","article-title":"Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo","volume":"43","author":"Forman","year":"1978","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"key20150804130551682_ref1-bib35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/BF00589130","article-title":"Selective suppression of some components of spontaneous activity in various types of smooth muscle by iproveratril (Verapamil)","volume":"331","author":"Golenhofen","year":"1972","journal-title":"Pflugers Archiv"},{"key":"key20150804130551682_ref1-bib36","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0022-5347(17)50121-4","article-title":"Calcium channel blockade in smooth muscle of the human upper urinary tract. II. Effects on norepinephrine-induced activation","volume":"132","author":"Hertle","year":"1984","journal-title":"J Urol"},{"key":"key20150804130551682_ref1-bib37","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0022-5347(17)50120-2","article-title":"Calcium channel blockade in smooth muscle of the human upper urinary tract. I. Effects on depolarization-induced activation","volume":"132","author":"Hertle","year":"1984","journal-title":"J Urol"},{"key":"key20150804130551682_ref1-bib38","first-page":"150","article-title":"Action of calcium antagonists on ureteral dynamics","volume":"13","author":"Salman","year":"1989","journal-title":"Actas Urol Esp"},{"key":"key20150804130551682_ref1-bib39","volume-title":"Tamsulosin Hydrochloride (Flomax Capsules 0.4 mg)","author":"Center for Drug Evaluation & Research","year":"1997"},{"key":"key20150804130551682_ref1-bib40","volume-title":"British National Formulary October 2014","author":"Joint Formulary Committee","year":"2014"},{"key":"key20150804130551682_ref1-bib41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.annemergmed.2007.05.015","article-title":"A systematic review of medical therapy to facilitate passage of ureteral calculi","volume":"50","author":"Singh","year":"2007","journal-title":"Ann Emerg Med"},{"key":"key20150804130551682_ref1-bib42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000338909","article-title":"Tamsulosin for ureteral stones: a systematic review and meta-analysis of a randomized controlled trial","volume":"89","author":"Lu","year":"2012","journal-title":"Urol Int"},{"key":"key20150804130551682_ref1-bib43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/iju.12048","article-title":"Can tamsulosin facilitate expulsion of ureteral stones? A meta-analysis of randomized controlled trials","volume":"20","author":"Fan","year":"2013","journal-title":"Int J Urol"},{"key":"key20150804130551682_ref1-bib44","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.eururo.2007.09.012","article-title":"Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones","volume":"53","author":"Bensalah","year":"2008","journal-title":"Eur Urol"},{"key":"key20150804130551682_ref1-bib45","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1464-410X.2010.09801.x","article-title":"A multicentre, prospective, randomized trial: comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic","volume":"108","author":"Ye","year":"2011","journal-title":"BJU Int"},{"key":"key20150804130551682_ref1-bib46","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJM199708213370806","article-title":"Discrepancies between meta-analyses and subsequent large randomized, controlled trials","volume":"337","author":"LeLorier","year":"1997","journal-title":"N Engl J Med"},{"key":"key20150804130551682_ref1-bib47","volume-title":"Guidelines on Urolithiasis","author":"Turk","year":"2014"},{"key":"key20150804130551682_ref1-bib48","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1089\/end.2007.0186","article-title":"Current practice patterns in the management of upper urinary tract calculi in the north central United States","volume":"22","author":"Bandi","year":"2008","journal-title":"J Endourol"},{"key":"key20150804130551682_ref1-bib49","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/ki.2012.419","article-title":"Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States","volume":"83","author":"Fwu","year":"2013","journal-title":"Kidney Int"},{"key":"key20150804130551682_ref1-bib50","doi-asserted-by":"publisher","first-page":"e925","DOI":"10.1016\/j.juro.2013.02.2166","article-title":"Medical expulsion therapy is underutilized in women presenting to an emergency department with acute urinary stone disease","volume":"189","author":"Bagga","year":"2013","journal-title":"J Urol"},{"key":"key20150804130551682_ref1-bib51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/1745-6215-15-238","article-title":"Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an alpha-blocker (tamsulosin): study protocol for a randomized controlled trial","volume":"15","author":"McClinton","year":"2014","journal-title":"Trials"},{"key":"key20150804130551682_ref1-bib52","volume-title":"UK Population Norms for EQ-5D. Discussion Paper 172","author":"Kind","year":"1999"},{"key":"key20150804130551682_ref1-bib53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/ard.37.4.378","article-title":"Studies with pain rating scales","volume":"37","author":"Downie","year":"1978","journal-title":"Ann Rheum Dis"},{"key":"key20150804130551682_ref1-bib54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0140-6736(48)91787-5","article-title":"The pain chart","volume":"2","author":"Keele","year":"1948","journal-title":"Lancet"},{"key":"key20150804130551682_ref1-bib55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"key20150804130551682_ref1-bib56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"key20150804130551682_ref1-bib57","volume-title":"EudraLex: The Rules Governing Medicinal Products in the European Union. Volume 4 EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Annex 13 Investigational Medicinal Products","author":"European Commission Enterprise and Industry Directorate-General","year":"2010"},{"key":"key20150804130551682_ref1-bib58","volume-title":"Data Protection Act 1998","author":"Great Britain","year":"1998"},{"key":"key20150804130551682_ref1-bib59","doi-asserted-by":"publisher","first-page":"MR000008","DOI":"10.1002\/14651858.mr000008.pub4","article-title":"Methods to increase response to postal and electronic questionnaires","volume":"3","author":"Edwards","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key20150804130551682_ref1-bib60","doi-asserted-by":"publisher","first-page":"MR000032","DOI":"10.1002\/14651858.mr000032.pub2","article-title":"Strategies to improve retention in randomised trials","volume":"12","author":"Brueton","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key20150804130551682_ref1-bib61","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"key":"key20150804130551682_ref1-bib62","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S0140-6736(05)61026-4","article-title":"Forest plots and the interpretation of subgroups","volume":"365","author":"Cuzick","year":"2005","journal-title":"Lancet"},{"key":"key20150804130551682_ref1-bib63","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(05)66461-6","article-title":"Multiplicity in randomised trials I: endpoints and treatments","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"key":"key20150804130551682_ref1-bib64","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/sim.1981","article-title":"Adjusting for partially missing baseline measurements in randomized trials","volume":"24","author":"White","year":"2005","journal-title":"Stat Med"},{"key":"key20150804130551682_ref1-bib65","doi-asserted-by":"publisher","first-page":"d40","DOI":"10.1136\/bmj.d40","article-title":"Strategy for intention to treat analysis in randomised trials with missing outcome data","volume":"342","author":"White","year":"2011","journal-title":"BMJ"},{"key":"key20150804130551682_ref1-bib66","volume-title":"NHS Reference Costs 2012\u201313","author":"Department of Health","year":"2014"},{"key":"key20150804130551682_ref1-bib67","volume-title":"Unit Costs of Health and Social Care 2013","author":"Curtis","year":"2013"},{"key":"key20150804130551682_ref1-bib68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"key20150804130551682_ref1-bib69","volume-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2007"},{"key":"key20150804130551682_ref1-bib70","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"key20150804130551682_ref1-bib71","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1067\/mem.2002.126170","article-title":"The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis","volume":"40","author":"Worster","year":"2002","journal-title":"Ann Emerg Med"},{"key":"key20150804130551682_ref1-bib72","doi-asserted-by":"publisher","first-page":"847","DOI":"10.4111\/kju.2011.52.12.847","article-title":"Expectant management of ureter stones: outcome and clinical factors of spontaneous passage in a single institution\u2019s experience","volume":"52","author":"Tchey","year":"2011","journal-title":"Korean J Urol"},{"key":"key20150804130551682_ref1-bib73","volume-title":"Flomax Relief MR (PL 00015\/0280)","author":"Medicines and Healthcare Products Regulatory Agency","year":"2009"},{"key":"key20150804130551682_ref1-bib74","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.psychres.2012.02.015","article-title":"Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression","volume":"197","author":"Weissman","year":"2012","journal-title":"Psychiatry Res"},{"key":"key20150804130551682_ref1-bib75","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00240-005-0508-0","article-title":"The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand?","volume":"33","author":"Autorino","year":"2005","journal-title":"Urol Res"},{"key":"key20150804130551682_ref1-bib76","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.urology.2007.01.009","article-title":"Comparative evaluation of efficacy of use of tamsulosin and\/or tolterodine for medical treatment of distal ureteral stones","volume":"69","author":"Erturhan","year":"2007","journal-title":"Urology"},{"key":"key20150804130551682_ref1-bib77","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00240-010-0257-6","article-title":"Does tamsulosin change the management of proximally located ureteral stones?","volume":"38","author":"Yencilek","year":"2010","journal-title":"Urol Res"},{"key":"key20150804130551682_ref1-bib78","volume-title":"Summary of Product Characteristics. Petyme","author":"Medicines & Healthcare products Regulatory Agency"},{"key":"key20150804130551682_ref1-bib79","volume-title":"Summary of Product Characteristics. Coracten","author":"Medicines & Healthcare products Regulatory Agency"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19630\/hta19630.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19630\/hta19630.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:35:40Z","timestamp":1692113740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta19630\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":79,"journal-issue":{"issue":"63","published-online":{"date-parts":[[2015,8]]}},"alternative-id":["10.3310\/hta19630"],"URL":"https:\/\/doi.org\/10.3310\/hta19630","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}